Figure 1.
Schematic diagram of liposomal drugs dosing and imaging schedule.
Mice were treated with liposomal drugs (NanoVNB, InNanoX, InVNBL and NanoX as a control) at Day 0, 7 and 14. Scintigraphic imaging of C26/tk-luc colon carcinoma-bearing mice treated with InVNBL was conducted on Day 2, 9, 16 and 22. Bioluminascence imaging was performed on Day 0, 4, 7, 11, 14 and 25.
Figure 2.
Relationship between tumor uptake (%ID/g) and tumor mass at 48 h after administration of InVNBL in mice bearing differently sized C26/tk-luc tumors.
Figure 3.
Body weight loss of the C26/tk-luc colon carcinoma-bearing mice after treatment with various liposomal drugs.
The mice bearing large tumor (n = 9 for each group, A) and those bearing small tumor (n = 6 for each group, B) were injected intravenously with NanoX (•), InNanoX (▽), NanoVNB (▪) or InVNBL (◊) at 0, 7, and 14 days after first injection (arrow; three injections total). The zero time point indicates the initiation of therapy. Data were expressed as mean ± S.E.M.
Figure 4.
Tumor growth curves of the C26/tk-luc colon carcinoma-bearing mice after treatment with various liposomal drugs.
The mice bearing large tumor (n = 9 for each group, tumor volume 102.4±22.0 mm3, A) and those bearing small tumor (n = 6 for each group, tumor volume 58.4±8.0 mm3, B) were injected intravenously with NanoX (•), InNanoX (▽), NanoVNB (▪) or InVNBL (◊) at 0, 7, and 14 days after first injection (arrow; three injections total). The zero time point indicates the initiation of therapy. Points, mean tumor sizes; bars, S.E.M.
Table 1.
The mean tumor growth inhibition rate of C26/tk-luc colon carcinoma-bearing mice on Day 25 since the 1st treatment.
Figure 5.
Survival fraction of the C26/tk-luc colon carcinoma-bearing mice after treatment with various liposomal drugs.
The mice bearing large tumor (n = 9 for each group, A) and those bearing small tumor (n = 6 for each group, B) were injected intravenously with NanoX (•), InNanoX (▽), NanoVNB (▪) or InVNBL (◊) at 0, 7, and 14 days after first injection (arrow; three injections total). Mice were euthanized when tumor volume greater than 2500 mm3.
Table 2.
Survival time of C26/tk-luc colon carcinoma-bearing mice that treated with various liposomal drugs.
Figure 6.
In vivo BLI of the C26/tk-luc colon carcinoma-bearing mice after treatment with various liposomal drugs.
The large-tumor mice receiving various liposomal drugs were intraperitoneally injected with 150 mg/kg d-luciferin 15 min prior to image acquisition at designated time points. The photons emitted from the mice (positioned prone) were acquired for 1 minute. The mice were anesthetized with 1∼3% isoflurane while conducting imaging.
Figure 7.
Whole-body scintigraphic images of the C26/tk-luc colon carcinoma-bearing mice at designated time points during the period of treatment with InNanoX and InVNBL.
The scintigraphic imaging was performed for 20 min at 48 h after drugs administration (37 MBq/100 µL per injection) and at 8 days after the last course of treatment. The mice were anesthetized with 1∼3% isoflurane for all imaging. Tumor nodules are indicated by red arrows.
Table 3.
Estimated parameters derived from scintigraphic images of C26/tk-luc colon carcinoma-bearing mice acquired after intravenous injection of 111In-containing liposomal drugs InNanoX and InVNBL (37 MBq/100 µL).